

References – Additional Reading

- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. *Neurourology and Urodynamics* 2002;21(2):167-78.
- Alhasso A, Glazener C, Pickard R, N'Dow J. Adrenergic drugs for urinary incontinence in adults. *Cochrane Database Syst Rev* 2005, Issue 3.
- American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). Accessed 2010 Mar 14 at <http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph>.
- Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. *Int J Urol* 2008 Oct;15(11):981-5.
- Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for urinary incontinence in post-menopausal women. *Cochrane Database Syst Rev* 2009, Issue 4.
- DiPiro J, Talbert R, Yee G, eds, et al. *Pharmacotherapy: A Pathophysiologic Approach*. 6th ed. New York, NY: McGraw-Hill; 2005: 1547-64.
- Dooley Y, Kenton K, Cao G, Luke A, Durazo-Arvizu R, Kramer H, et al. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. *J Urol* 2008 Feb;179(2):656-61.
- DuBeau C. Treatment of urinary incontinence. *UpToDate*. Last updated 2009 Oct 16.
- Griebeling TL. Urinary incontinence in the elderly. *Clin Geriatr Med* 2009;25:445-57.
- Hay-Smith J, Ellis G, Herbison GP. Which anticholinergic drug for overactive bladder symptoms in adults. *Cochrane Database Syst Rev* 2005, Issue 3.
- Hunsballe J, Djurhuus J. Clinical options for imipramine in the management of urinary incontinence. *Urol Res* 2001; 29:118-25.
- Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al; Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. *Urology* 2003 Jan;61(1):119-26.
- Lee M, Yeager B. The Pharmacist's role in the management of lower urinary tract symptoms. *American Pharmacist's Association Highlights Newsletter* 2004; 7(3):1-6.
- Lexi-Comp, Inc. [Lexi-Drugs (Comp + Specialties)]. Accessed 2010 Feb 1.
- Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: A systematic review. *Eur Urol* 2007; 51:67-74.
- McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med* 2003 Dec 18;349(25):2387-98.
- Micromedex Healthcare Series. Accessed 2010 Mar 8 at <http://www.thomsonhc.com>.
- Planinz TA. Herbs for bladder incontinence. 2009 Dec 30. Accessed 2010 Mar 14 at <http://www.livestrong.com/article/68643-herbs-bladder-incontinence/>.
- Robb-Nicholson C. The October issue: By the way, doctor [editorial]. *Harv Womens Health Watch* 2009; 17(2):8.
- Robinson D, Cardozo L. New drug treatments for urinary incontinence. *Maturitas* 2010.
- Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. *BJU Int* 2008 Nov;102 Suppl 2:13-7.
- Rovner E, Wein A. Treatment options for stress urinary incontinence. *Rev Urol* 2004;6(suppl 3):S29-S47.
- Shaban A, Drake M, Hashim H. The medical management of urinary incontinence. *Auton Neurosci: Basic and Clinical* 2010;152:4-10.
- Wu J, Hundley A, Fulton R, Myers E. Forecasting the prevalence of pelvic floor disorders in U.S. women: 2010 to 2050. *Obstet Gynecol* 2009; 114(6):1278-83.